Dr Boby Mihaylova
|Tel||+44 (0)1865 289226|
Associate Professor and University Research Lecturer
- Health Economics Research Centre
Borislava (Boby) Mihaylova is a University Research Lecturer and a Senior Researcher in Health Economics at the Health Economics Research Centre at the University of Oxford. Her research programme focuses on economic aspects of chronic disease (such as cardiovascular, chronic kidney disease and diabetes) and comprises studies of the impact of disease events and interventions on morbidity, mortality, health-related quality of life and healthcare costs; development of disease models to evaluate long-term effects of disease and interventions, cost-effectiveness analyses of healthcare interventions and studies of socio-economic determinants of health. She is leading the development of the economic analyses in a number of large randomised controlled trials (SHARP, THRIVE, REVEAL and ACST-2) and in the individual participant data meta-analysis of statin trials (Cholesterol Treatment Collaboration). Her work on effectiveness and cost-effectiveness of statins for cardiovascular disease prevention in the Heart Protection Study and the Cholesterol Treatment Collaboration has been influential in informing treatment recommendations for people at different vascular disease risk.
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
Herrington W. et al, (2016), The Lancet Diabetes and Endocrinology
The Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin with Laropiprant on Health and Healthcare Costs
Mihaylova BN. et al, (2016), Circulation: Cardiovascular Quality and Outcomes
Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs
Seamus Kent et al, (2016), Circulation: Cardiovascular Quality and Outcomes
Protocol for analyses of adverse event data from randomized controlled trials of statin therapy
(2016), American Heart Journal, 176, 63 - 69
The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review.
Morton RL. et al, (2016), Nephrol Dial Transplant, 31, 46 - 56